Evidence map›Paper›PMID 42016295›Full record

ArticleEFSA journal. European Food Safety Authority2026

Safety of 3'-sialyllactose (3'-SL) sodium salt produced with a derivative strain (

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty and 13 more

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA)
Dominique Turck
Torsten Bohn
Montaña Cámara
Jacqueline Castenmiller
Stefaan De Henauw
Ángeles Jos
Alexandre Maciuk
Inge Mangelsdorf
Breige McNulty
Androniki Naska
Kristina Pentieva
Alfonso Siani
Frank Thies
Margarita Aguilera-Gómez
Thomas Frenzel
Harry J McArdle
Peter Moldeus
Monika Neuhäuser-Berthold
Josef Rudolf Schlatter
Henk van Loveren
Estefanía Noriega Fernández
Karen Ildico Hirsch-Ernst

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3'-sialyllactose (3'-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 3'-SL (sodium salt), but it also contains d-lactose, sialic acid, 3'-sialyllactulose and a small fraction of other related saccharides. The NF is produced by fermentation with a genetically modified strain (

Indexed as

3′‐sialyllactose3′‐SLHiMOHMOhuman milk oligosaccharidenovel foodsafety

Identifiers

PMID42016295
PMCPMC13093741

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.